I have had three Seeking Alpha articles published since my last post:
Regeneron Pipeline Worth Tens of Billions in Market Capitalization
Mylan Pursues Global Generics Dominance Strategy
Intuitive Surgical Market Saturation Could Be Brief
All three of these biotechnology companies are part of the Nasdaq 100, which I have been plowing through, looking toward my next round of investment. Each has something unique to offer. As detailed in the articles, each of them, at the current price and based on current information, looks like a good long-term investment. But I'll be doing considerably more research before making any actual purchases.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment